Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HENRY MARK KUERER and MEDIGET TESHOME.
HENRY MARK KUERER
Connection Strength
3.532
MEDIGET TESHOME
  1. Breast conserving surgery and locoregional control after neoadjuvant chemotherapy. Eur J Surg Oncol. 2017 May; 43(5):865-874.
    View in: PubMed
    Score: 0.579
  2. Training of breast surgical oncologists. Chin Clin Oncol. 2016 Jun; 5(3):43.
    View in: PubMed
    Score: 0.549
  3. ASO Visual Abstract: Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol. 2025 Jan; 32(1):123-124.
    View in: PubMed
    Score: 0.250
  4. Impact of Clipped Node as a Sentinel Lymph Node on Axillary Staging Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer. Ann Surg Oncol. 2025 Jan; 32(1):84-91.
    View in: PubMed
    Score: 0.246
  5. Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes at Targeted Axillary Dissection. Ann Surg Oncol. 2024 Oct; 31(11):7264-7270.
    View in: PubMed
    Score: 0.242
  6. Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection. Ann Surg Oncol. 2023 Nov; 30(12):7015-7025.
    View in: PubMed
    Score: 0.226
  7. Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2021 Oct; 28(10):5477-5485.
    View in: PubMed
    Score: 0.196
  8. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079.
    View in: PubMed
    Score: 0.171
  9. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
    View in: PubMed
    Score: 0.157
  10. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
    View in: PubMed
    Score: 0.149
  11. ASO Visual Abstract: Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2024 Nov 19.
    View in: PubMed
    Score: 0.062
  12. Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2024 Oct 23.
    View in: PubMed
    Score: 0.062
  13. Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Netw Open. 2024 Jun 03; 7(6):e2418486.
    View in: PubMed
    Score: 0.060
  14. Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. Ann Surg Oncol. 2024 Feb; 31(2):974-980.
    View in: PubMed
    Score: 0.058
  15. Long-Term Outcomes and Predictors of Response in Breast Cancer Patients with Advanced Nodal Involvement. J Am Coll Surg. 2024 01 01; 238(1):1-9.
    View in: PubMed
    Score: 0.058
  16. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer? Ann Surg Oncol. 2023 Dec; 30(13):8327-8334.
    View in: PubMed
    Score: 0.057
  17. Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol. 2022 Oct; 29(10):6381-6392.
    View in: PubMed
    Score: 0.053
  18. Impact of the early COVID-19 pandemic on Breast Surgical Oncology fellow education. J Surg Oncol. 2021 Dec; 124(7):989-994.
    View in: PubMed
    Score: 0.049
  19. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Dec; 28(13):8610-8621.
    View in: PubMed
    Score: 0.049
  20. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Aug; 28(8):4265-4274.
    View in: PubMed
    Score: 0.047
  21. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open. 2020 Dec; 1(2).
    View in: PubMed
    Score: 0.047
  22. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? Ann Surg Oncol. 2020 Nov; 27(12):4603-4612.
    View in: PubMed
    Score: 0.046
  23. Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Pract Radiat Oncol. 2019 Nov; 9(6):402-409.
    View in: PubMed
    Score: 0.042
  24. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. Ann Surg Oncol. 2019 Mar; 26(3):815-820.
    View in: PubMed
    Score: 0.041
  25. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol. 2017 Mar; 24(3):652-659.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.